JBJoanna C. Betts

Joanna C. Betts

*This is an algorithmically generated author record based on publicly available information.

Joanna C. Betts has a total of 146 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical and Molecular Effect of the Anti– IL ‐18 Antibody Aletekitug in Adults With Atopic Dermatitis

    by Joanne Ellis, Léa Fortunato, Hannah Wajdner, Ester Del Duca, Joanna Barnard, Joanna C. Betts, Swaroop Bose, John Browning, Núria Buil‐Bruna, Scott Van Buren, et al.

    Background: Interleukin‐18 (IL‐18) is a pleiotropic cytokine implicated in atopic dermatitis (AD), affecting both type (T)1 and T2 immune pathways. An anti–IL‐18 monoclonal antibody, aletekitug, was evaluated for its clinical and molecular effects in patients with moderate to severe AD. Methods: This randomised, double‐blind, parallel‐group, placebo‐controlled, 24‐week study assessed adults with moderate‐to‐severe AD who were biologic‐naïve or dupilumab‐inadequate responders/intolerant. Participants received a single intravenous (IV) infusion of aletekitug 2 mg/kg or placebo. The primary endpoint was percentage change from baseline (PCFB) in Eczema Area and Severity Index (EASI) score at Week 12. Other endpoints included safety, patient‐reported outcomes (PROs) and transcriptomics. Results: Thirty‐four participants (aletekitug, n = 23; placebo, n = 11) were randomised. A greater reduction in the PCFB in EASI score at Week 12 was demonstrated for patients who received aletekitug versus placebo (posterior median PCFB [95% credible intervals]: aletekitug, −68.3% [−79.68, −56.68]; placebo, −32.9% [−45.74, −21.10]), with effects still apparent at Week 24. Aletekitug improved PRO measures of itch, sleep disturbance, fatigue and quality of life versus placebo up to Week 24. Transcriptome analysis suggested aletekitug modulated lesional skin towards a non‐lesional profile and exerted broad immunomodulatory effects, impacting several AD‐associated signalling pathways, not limited to T2 immunity. Aletekitug was well tolerated, with no serious adverse events reported. Conclusion: A single 2 mg/kg IV dose of aletekitug was associated with improved outcomes at Week 12, which were sustained to Week 24, and modulated immune mechanisms beyond T2 inflammation. These results support IL‐18 as a potential therapeutic target in moderate‐to‐severe AD.


  • Open Access

    Single-Step, High-Efficiency CRISPR-Cas9 Genome Editing in Primary Human Disease-Derived Fibroblasts

    by Matteo Martufi, Robert B. Good, Radu Rapiteanu, Tobias Schmidt, Eleni Patili, Ketil Tvermosegaard, Maria New, Carmel B. Nanthakumar, Joanna Betts, Andy D. Blanchard, et al.

    Genome editing is a tool that has many applications, including the validation of potential drug targets. However, performing genome editing in low-passage primary human cells with the greatest physiological relevance is notoriously difficult. High editing efficiency is desired because it enables gene knockouts (KO) to be generated in bulk cellular populations and circumvents the problem of having to generate clonal cell isolates. Here, we describe a single-step workflow enabling >90% KO generation in primary human lung fibroblasts via CRISPR ribonucleoprotein delivery in the absence of antibiotic selection or clonal expansion. As proof of concept, we edited two SMAD family members and demonstrated that in response to transforming growth factor beta, SMAD3, but not SMAD2, is critical for deposition of type I collagen in the fibrotic response. The optimization of this workflow can be readily transferred to other primary cell types.


  • Open Access

    Single step, high efficiency CRISPR-Cas9 genome editing in primary human disease-derived fibroblasts

    by Matteo Martufi, Robert B. Good, Radu Rapiteanu, Tobias Schmidt, Eleni Patili, Ketil Tvermosegaard, Carmel B. Nanthakumar, Joanna Betts, Andy D. Blanchard, Klio Maratou

    Genome editing is a tool that has many applications including the validation of potential drug targets. However, performing genome editing in low passage, primary human cells with the greatest physiological relevance, is notoriously difficult. High editing efficiency is desired because it enables gene knock outs (KO) to be generated in bulk cellular populations and circumvents the problem of having to generate clonal cell isolates. Here, we describe a single step workflow enabling >90% KO generation in primary human lung fibroblasts via CRISPR ribonucleoprotein delivery, in the absence of antibiotic selection or clonal expansion. As proof of concept, we performed a disease relevant phenotypic assay measuring collagen deposition in response to TGFβ and demonstrated SMAD3 but not SMAD2 dependent deposition of type I collagen following knockout of each using our single step methodology. The optimization of this workflow can readily be transferred to other primary cell types.


  • Open Access

    Linking rare and common disease: mapping clinical disease-phenotypes to ontologies in therapeutic target validation

    by Sirarat Sarntivijai, Drashtti Vasant, Simon Jupp, Gary Saunders, A. Patrícia Bento, Daniel Gonzalez, Joanna Betts, Samiul Hasan, Gautier Koscielny, Ian Dunham, et al.

    The Centre for Therapeutic Target Validation (CTTV - https://www.targetvalidation.org/ ) was established to generate therapeutic target evidence from genome-scale experiments and analyses. CTTV aims to support the validity of therapeutic targets by integrating existing and newly-generated data. Data integration has been achieved in some resources by mapping metadata such as disease and phenotypes to the Experimental Factor Ontology (EFO). Additionally, the relationship between ontology descriptions of rare and common diseases and their phenotypes can offer insights into shared biological mechanisms and potential drug targets. Ontologies are not ideal for representing the sometimes associated type relationship required. This work addresses two challenges; annotation of diverse big data, and representation of complex, sometimes associated relationships between concepts. Semantic mapping uses a combination of custom scripting, our annotation tool ‘Zooma’, and expert curation. Disease-phenotype associations were generated using literature mining on Europe PubMed Central abstracts, which were manually verified by experts for validity. Representation of the disease-phenotype association was achieved by the Ontology of Biomedical AssociatioN (OBAN), a generic association representation model. OBAN represents associations between a subject and object i.e., disease and its associated phenotypes and the source of evidence for that association. The indirect disease-to-disease associations are exposed through shared phenotypes. This was applied to the use case of linking rare to common diseases at the CTTV. EFO yields an average of over 80 % of mapping coverage in all data sources. A 42 % precision is obtained from the manual verification of the text-mined disease-phenotype associations. This results in 1452 and 2810 disease-phenotype pairs for IBD and autoimmune disease and contributes towards 11,338 rare diseases associations (merged with existing published work [Am J Hum Genet 97:111-24, 2015]). An OBAN result file is downloadable at http://sourceforge.net/p/efo/code/HEAD/tree/trunk/src/efoassociations/ . Twenty common diseases are linked to 85 rare diseases by shared phenotypes. A generalizable OBAN model for association representation is presented in this study. Here we present solutions to large-scale annotation-ontology mapping in the CTTV knowledge base, a process for disease-phenotype mining, and propose a generic association model, ‘OBAN’, as a means to integrate disease using shared phenotypes. EFO is released monthly and available for download at http://www.ebi.ac.uk/efo/ .


  • Open Access

    Gene expression changes caused by the p38 MAPK inhibitor dilmapimod in COPD patients: analysis of blood and sputum samples from a randomized, placebo‐controlled clinical trial

    by Joanna C. Betts, Ruth J. Mayer, Ruth Tal‐Singer, Linda Warnock, Chris Clayton, Stewart Bates, Bryan E. Hoffman, Christopher Larminie, Dave Singh

    The p38 mitogen‐activated protein kinase (MAPK) intracellular signaling pathway responds to a variety of extracellular stimuli, including cytokines, Toll‐like receptor agonists, and components of cigarette smoke to influence the expression of proinflammatory mediators. Activation of p38 MAPK is increased within the lungs of chronic obstructive pulmonary disease (COPD) patients. In clinical trials, treatment of COPD patients with p38 MAPK inhibitors has been shown to reduce systemic inflammation plasma biomarkers C‐reactive protein (CRP) and fibrinogen. As CRP and fibrinogen have been associated with poor clinical outcomes in COPD patients, such as mortality, exacerbation, and hospitalization, we analyzed gene expression data from COPD subjects treated with dilmapimod with the aim of understanding the effects of p38 MAPK inhibition on the inflammatory genome of immune cells within the systemic circulation. Whole blood and induced sputum samples were used to measure mRNA levels by gene array and PCR. Pathway and network analysis showed STAT1, MMP‐9, CAV1, and IL‐1β as genes regulated by dilmapimod that could also influence fibrinogen levels, while only IL‐1β was identified as a gene regulated by dilmapimod that could influence CRP levels. This suggests that p38 MAPK inhibits specific inflammatory pathways, leading to to differential effects on CRP and fibrinogen levels in COPD patients.


  • Protein expression by a Beijing strain differs from that of another clinical isolate and Mycobacterium tuberculosis H37Rv

    by Carmen Pheiffer, Joanna C. Betts, Helen R. Flynn, Pauline T. Lukey, Paul van Helden

    The Beijing strain family has often been associated with tuberculosis (TB) outbreaks and drug resistance worldwide. In this study the authors have compared the protein expression and antigen recognition profiles of a local Beijing strain with a less prevalent clinical isolate belonging to the family 23 strain lineage, and the laboratory strain Mycobacterium tuberculosis H37Rv. Using two-dimensional electrophoresis, liquid chromatography tandem mass spectrometry and Western blot analysis several proteins were identified as quantitatively increased or decreased in both clinical strains compared to H37Rv. Remarkably, the Beijing strain showed increased expression of α-crystallin and decreased expression of Hsp65, PstS1, and the 47 kDa protein compared to the other clinical strain and H37Rv. One- and two-dimensional Western blot analysis of antigens expressed by the three strains, using plasma from TB patients, confirmed differential antigen expression by strains and patient-to-patient variation in humoral immunity. These observed protein differences could aid the elucidation of mechanisms underlying the success of the Beijing strain family, measured by global dissemination, compared to other M. tuberculosis strains.


  • Open Access

    The Mycobacterium tuberculosis protein serine/threonine kinase PknG is linked to cellular glutamate/glutamine levels and is important for growth in vivo

    by Siobhan Cowley, Mary Ko, Neora Pick, Rayken Chow, Katrina J. Downing, Bhavna G. Gordhan, Joanna C. Betts, Valerie Mizrahi, Debbie A. Smith, Richard W. Stokes, et al.

    Summary The function of the Mycobacterium tuberculosis eukaryotic‐like protein serine/threonine kinase PknG was investigated by gene knock‐out and by expression and biochemical analysis. The pknG gene (Rv0410c), when cloned and expressed in Escherichia coli, encodes a functional kinase. An in vitro kinase assay of the recombinant protein demonstrated that PknG can autophosphorylate its kinase domain as well as its 30 kDa C‐terminal portion, which contains a tetratricopeptide (TPR) structural signalling motif. Western analysis revealed that PknG is located in the cytosol as well as in mycobacterial membrane. The pknG gene was inactivated by allelic exchange in M. tuberculosis. The resulting mutant strain causes delayed mortality in SCID mice and displays decreased viability both in vitro and upon infection of BALB/c mice. The reduced growth of the mutant was more pronounced in the stationary phase of the mycobacterial growth cycle and when grown in nutrient‐depleted media. The PknG‐deficient mutant accumulates glutamate and glutamine. The cellular levels of these two amino acids reached approximately threefold of their parental strain levels. Higher cellular levels of the amine sugar‐containing molecules, GlcN‐Ins and mycothiol, which are derived from glutamate, were detected in the ΔpknG mutant. De novo glutamine synthesis was shown to be reduced by 50%. This is consistent with current knowledge suggesting that glutamine synthesis is regulated by glutamate and glutamine levels. These data support our hypothesis that PknG mediates the transfer of signals sensing nutritional stress in M. tuberculosis and translates them into metabolic adaptation.


  • The Mycobacterium tuberculosis dosRS two-component system is induced by multiple stresses

    by S.L Kendall, F Movahedzadeh, S.C.G Rison, L Wernisch, T Parish, K Duncan, J.C Betts, N.G Stoker


  • Open Access

    Signature Gene Expression Profiles Discriminate between Isoniazid-, Thiolactomycin-, and Triclosan-Treated Mycobacterium tuberculosis

    by Joanna C. Betts, Alistair McLaren, Mark G. Lennon, Fiona M. Kelly, Pauline T. Lukey, Steve J. Blakemore, Ken Duncan

    Genomic technologies have the potential to greatly increase the efficiency of the drug development process. As part of our tuberculosis drug discovery program, we used DNA microarray technology to profile drug-induced effects in Mycobacterium tuberculosis . Expression profiles of M. tuberculosis treated with compounds that inhibit key metabolic pathways are required as references for the assessment of novel antimycobacterial agents. We have studied the response of M. tuberculosis to treatment with the mycolic acid biosynthesis inhibitors isoniazid, thiolactomycin, and triclosan. Thiolactomycin targets the β-ketoacyl-acyl carrier protein (ACP) synthases KasA and KasB, while triclosan inhibits the enoyl-ACP reductase InhA. However, controversy surrounds the precise mode of action of isoniazid, with both InhA and KasA having been proposed as the primary target. We have shown that although the global response profiles of isoniazid and thiolactomycin are more closely related to each other than to that of triclosan, there are differences that distinguish the mode of action of these two drugs. In addition, we have identified two groups of genes, possibly forming efflux and detoxification systems, through which M. tuberculosis may limit the effects of triclosan. We have developed a mathematical model, based on the expression of 21 genes, which is able to perfectly discriminate between isoniazid-, thiolactomycin-, or triclosan-treated M. tuberculosis . This model is likely to prove invaluable as a tool to improve the efficiency of our drug development programs by providing a means to rapidly confirm the mode of action of thiolactomycin analogues or novel InhA inhibitors as well as helping to translate enzyme activity into whole-cell activity.